{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:44:45Z","timestamp":1776329085282,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T00:00:00Z","timestamp":1310601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:bold>What\u2019s known on the subject? and<\/jats:bold>\n                      What does the study add?\n                    <\/jats:p>\n                    <jats:p>Estramustine phosphate has anti\u2010tumour properties and it improves patient outcomes if combined with other chemotherapy agents such as doeetaxel.<\/jats:p>\n                    <jats:p>The efficacy of estramustine phosphate in selected patients and its safety profile, provided used with any low\u2010molecular\u2010weight heparin support its use as a second\u2010line treatment in hormone\u2010resistant prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Estramustine phosphate is a nitrogen mustard derivative of estradiol\u201017\u03b2\u2010phosphate and has anti\u2010tumour properties.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Interest in estramustine has been renewed because of the results of clinical studies showing improved patient outcomes if estramustine is combined with other chemotherapy agents such as docetaxel.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Relevant clinical studies using chemotherapy combinations including estramustine are discussed.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Efficacy and safety outcomes are summarized.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Combination therapy with estramustine and docetaxel can increase PSA response rates, improve quality of life and increase median patient survival compared with chemotherapy regimens that do not include estramustine.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Although the overall tolerability of estramustine is favourable, its use can be associated with an increased risk of thromboembolic events.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>The identification of suitable patient groups and the effective management of the risk of thromboembolism with the adjunct of low\u2010molecular\u2010weight heparins support the use of estramustine as an effective second\u2010line treatment strategy in hormone\u2010resistant prostate cancer.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>These promising findings warrant further investigation in a randomized clinical trial.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2011.10201.x","type":"journal-article","created":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T08:52:17Z","timestamp":1310633537000},"page":"1782-1786","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The use of estramustine phosphate in the modern management of advanced prostate cancer"],"prefix":"10.1111","volume":"108","author":[{"given":"Vincent","family":"Ravery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Drouet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Christophe","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,14]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1756"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2506"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199507010-00006"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.187"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm083"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07779.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.9524"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2008.07.033"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008394823889"},{"key":"e_1_2_8_13_2","first-page":"769","article-title":"Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen\u2010resistant prostate cancer: a single institution experience","volume":"29","author":"Pectasides D","year":"2009","journal-title":"Anticancer Res"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.02.023"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.2274"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70284-X"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20673"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1079260"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-142422"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.002"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_8_22_2","article-title":"Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer","author":"Akl EA","year":"2008","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10201.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10201.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:26:56Z","timestamp":1761737216000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10201.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,14]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10201.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10201.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,14]]},"assertion":[{"value":"2011-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}